
Contents

<i>List of contributors</i>	vii
<i>Preface</i> Carlos M. Correa	x

PART I HISTORY, INTERPRETATION AND PRINCIPLES

1. Why IPR issues were brought to GATT: a historical perspective on the origins of TRIPS <i>Charles Clift</i>	3
2. Developing countries in the global IP system before TRIPS: the political context for the TRIPS negotiations <i>Carolyn Deere-Birkbeck</i>	22
3. Minimum standards vs. harmonization in the TRIPS context: the nature of obligations under TRIPS and modes of implementation at the national level in monist and dualist systems <i>Denis Borges Barbosa</i>	52
4. Enhancing global innovation policy: the role of WIPO and its Conventions in interpreting the TRIPS Agreement <i>Graeme B. Dinwoodie and Rochelle C. Dreyfuss</i>	110
5. The objectives and principles of the TRIPS Agreement <i>Peter K. Yu</i>	146
6. Mainstreaming the TRIPS and human rights interactions <i>Xavier Seuba</i>	192
7. The TRIPS Agreement and intellectual property rights exhaustion <i>Luis Mariano Genovesi</i>	216
8. Intellectual property rights and competition policy <i>Beatriz Conde Gallego</i>	226
9. Intellectual property rights in free trade agreements: moving beyond TRIPS minimum standards <i>Pedro Roffe, Christoph Spennemann and Johanna von Braun</i>	266

PART II SUBSTANTIVE RIGHTS

10.	Limits, limitations and exceptions to copyright under the TRIPS Agreement <i>P. Bernt Hugenholtz</i>	319
11.	Copyright in TRIPS and beyond: the WIPO Internet Treaties <i>Ruth L. Okediji</i>	343
12.	The protection of 'related rights' in TRIPS and the WIPO Performances and Phonograms Treaty <i>Owen Morgan</i>	379
13.	Marks for goods or services (trademarks) <i>Annette Kur</i>	408
14.	Unresolved issues on geographical indications in the WTO <i>Kasturi Das</i>	448
15.	No 'lemons' no more: a sketch on the 'economics' of geographical indications <i>Dwijen Rangnekar</i>	515
16.	Exploring the flexibilities of TRIPS to promote biotechnology in developing countries <i>Graham Dutfield, Lois Muraguri and Florian Lerve</i>	540
17.	Compulsory licensing of patented pharmaceutical inventions: evaluating the options <i>Jerome H. Reichman</i>	589
18.	The Doha Declaration and access to medicines by countries without manufacturing capacity <i>S.K. Verma</i>	623
19.	Disease-based limitations on compulsory licenses under Articles 31 and 31bis <i>Kevin Outterson</i>	673
20.	The protection of semiconductor chip products in TRIPS <i>Thomas Hoeren</i>	698
21.	Data exclusivity for pharmaceuticals: TRIPS standards and industry's demands in free trade agreements <i>Carlos M. Correa</i>	713
	<i>Index</i>	729